Brief: Newamsterdam Pharma Announces Positive Alzheimer’S Disease Data From Broadway Clinical Trial
09/06/2025 12:18
June 9 (Reuters) - NewAmsterdam Pharma Company NV KH6.F: NEWAMSTERDAM PHARMA ANNOUNCES POSITIVE TOPLINE ALZHEIMER’S DISEASE DATA FROM BROADWAY CLINICAL TRIAL NEWAMSTERDAM PHARMA COMPANY NV - OBICETRAPIB SHOWS SIGNIFICANT REDUCTIONS IN ALZHEIMER'S BIOMARKER Source text: ID:nGNX9g2d0X Further company coverage: KH6.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewAmsterdam Pharma
See all newsBrief: Menarini Group & Newamsterdam Pharma Receive European Commission Approval For Ubeslo And Evlarco
Amgen falls after Novartis trial setback, BMO downgrade
Brief: Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion For Obicetrapib And Obicetrapib/Ezetimibe
Brief: NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)